Is XBiotech Inc. (XBIT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.3% / 30% | 241.0% / 30% | 1.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 14.3% / 33% | 241.0% / 33% | 1.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 5.1% / 33% | 86.7% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 14.3% / 33% | 241.0% / 33% | 1.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 5.1% / 33% | 86.7% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -28.2% | |
| Return on Assets (ROA) | -19.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$40M |
| Free Cash Flow | -$40M |
| Current Ratio | 16.0 |
| Total Assets | $150M |
Price & Trading
| Last Close | $2.31 |
| 50-Day MA | $2.40 |
| 200-Day MA | $2.63 |
| Avg Volume | 45K |
| Beta | 0.9 |
|
52-Week Range
$2.09
| |
About XBiotech Inc. (XBIT)
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is XBiotech Inc. (XBIT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), XBiotech Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is XBiotech Inc.'s debt ratio?
XBiotech Inc.'s debt ratio is 14.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.1%.
What are XBiotech Inc.'s key financial metrics?
XBiotech Inc. has a market capitalization of $69M. Return on equity stands at -28.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.